The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic …
M Takahashi, T Ohara, H Yamanaka… - Palliative …, 2003 - journals.sagepub.com
To provide additional pharmacokinetic evidence for the oral-to-parenteral relative potency
ratio of 1: 2 to 1: 3 for chronic morphine use in a palliative care setting, we determined the …
ratio of 1: 2 to 1: 3 for chronic morphine use in a palliative care setting, we determined the …
Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by …
P Klepstad, S Kaasa, PC Borchgrevink - European journal of clinical …, 2000 - Springer
Objective: To investigate the serum concentrations of morphine, morphine-3-glucuronide
(M3G) and morphine-6-glucuronide (M6G) and the relationships between serum …
(M3G) and morphine-6-glucuronide (M6G) and the relationships between serum …
[HTML][HTML] A prospective population pharmacokinetic study on morphine metabolism in cancer patients
Background Oral and subcutaneous morphine is widely used for the treatment of cancer-
related pain; however, solid pharmacokinetic data on this practice are lacking. Furthermore …
related pain; however, solid pharmacokinetic data on this practice are lacking. Furthermore …
Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients
A Vermeire, JP Remon, MT Rosseel, F Belpaire… - European journal of …, 1998 - Springer
Objective: To study the plasma concentrations of morphine and its glucuronides to assess
the intra-and interindividual variability of the disposition of morphine administered by …
the intra-and interindividual variability of the disposition of morphine administered by …
Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with …
C Quigley, S Joel, N Patel, A Baksh… - Palliative …, 2003 - journals.sagepub.com
Morphine, the recommended drug for the management of moderate to severe cancer pain, is
metabolized predominantly to the glucuronides morphine-6-glucuronide (M6G) and …
metabolized predominantly to the glucuronides morphine-6-glucuronide (M6G) and …
Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer …
P Klepstad, PC Borchgrevink, O Dale… - Palliative …, 2003 - journals.sagepub.com
The clinical importance of routine drug monitoring of serum concentrations of morphine,
morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic …
morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic …
Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration
T Wolff, H Samuelsson, T Hedner - Pain, 1995 - Elsevier
In 34 cancer patients treated with chronic slow-release oral morphine, plasma and
cerebrospinal fluid (CSF) minimum steady-state concentrations of morphine (M), morpine-3 …
cerebrospinal fluid (CSF) minimum steady-state concentrations of morphine (M), morpine-3 …
Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences …
RK Portenoy, KM Foley, J Stulman, E Khan, J Adelhardt… - Pain, 1991 - Elsevier
Abstract Morphine-6-glucuronide (M-6-G) is an active metabolite of morphine that may
contribute to drug effects. To understand better the relationship between morphine and M-6 …
contribute to drug effects. To understand better the relationship between morphine and M-6 …
[HTML][HTML] Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an …
YJ Lee, SY Suh, J Song, SS Lee, AR Seo, HY Ahn… - BMC Palliative Care, 2015 - Springer
Background The feasibility and clinical implication of drug monitoring of morphine, morphine-
6-glucuronide (M6G) and morphine-3-glucuronide (M3G) need further investigation. This …
6-glucuronide (M6G) and morphine-3-glucuronide (M3G) need further investigation. This …
[HTML][HTML] Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer …
P Klepstad, P Hilton, J Moen, S Kaasa… - BMC Clinical …, 2004 - Springer
Background The feasibility of drug monitoring of serum concentrations of morphine,
morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic …
morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic …